Can Risedronate Prevent Periprosthetic Bone Loss After Total Hip Arthroplasty

Can Risedronate Prevent Periprosthetic Bone Loss After Total Hip Arthroplasty. A Randomized, Double-blind, Placebo-controlled, Parallel-group Study

Can risedronate given once weekly for 6 months prevent periprosthetic bone loss after uncemented total hip arthroplasty?

Periprosthetic bone loss after total hip arthroplasty is the main factor in limiting the longevity of implants used for treatment of osteoarthritis. Bone loss leads to implant destabilization. Bisphosphonates, given for approximately 6 months after THA man prevent this bone loss and lead to longer implant fixation and lower incidence of aseptic prosthesis loosening. We perform a clinical trial with risedronate to investigate if we can influence periprosthetic bone loss around a uncemented femoral stem.

Inclusion Criteria:

• Patients on the waiting list for a total hip arthroplasty
• Primary osteoarthritis
• Osteoarthritis secondary to congenital dislocation of the hip

Exclusion Criteria:

• Rheumatoid arthritis
• Bisphosphonate treatment
• Osteomalacia
• Hypocalcemia
• Previous surgery of the affected hip